Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International, has launched its Acanya gel indicated for the once-daily treatment of acne vulgaris in patients 12 years and older.
Subscribe to our email newsletter
According to the company, Acanya gel is the only FDA-approved fixed combination antibiotic and benzoyl peroxide (BPO) medication for once-daily treatment of both non-inflammatory and inflammatory lesions of acne. Formulated in an aqueous-based, alcohol-free gel, Acanya gel was optimized to provide enhanced bioavailability of BPO, creating an effective and well tolerated product.
In pivotal Phase III clinical trials, Acanya gel showed superior efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent tolerability and very high patient satisfaction scores, the company said.
Acanya gel was developed by Arcutis Pharmaceuticals, now a part of Coria Laboratories, a division of Valeant Pharmaceuticals International. Acanya gel is protected by two US patents and has pending patent applications.
Diane Thiboutot, a Phase III trial investigator, said: “The new fixed combination, Acanya gel, is an effective, safe, and well-tolerated topical product for treating patients with moderate to severe inflammatory and non-inflammatory acne. In addition, high levels of patient satisfaction with Acanya gel point to the potential for increased patient adherence to treatment, and thus, to improved clinical outcomes.”